|Budget Amount *help
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|Outline of Final Research Achievements
To clarify tumor heterogeneity in acute myeloid leukemia (AML), we performed multi-sampling and whole-exome sequencing in two AML autopsy cases. The specimens examined included those obtained from bone marrow (5-7 sites), peripheral blood, plasma, and buccal smear (germline control). As a result, we identified 28-68 mutations in these samples, consisting of shared and private mutations. Interestingly, we found that the more distant the compared bone marrow sites, the more the number of private mutations between them. These results suggest the presence of tumor heterogeneity and its feature in AML.